New horizons in the treatment of renal cell cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Wagstaff, J ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASBESTOS; BEVACIZUMAB; CALCIUM; CARBONATE DEHYDRATASE IX; ERLOTINIB; ERYTHROPOIETIN; FLUOROURACIL; FUMARATE HYDRATASE; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON; INTERLEUKIN 2; LACTATE DEHYDROGENASE; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT INTERFERON; RETINOID; SORAFENIB; SUCCINATE DEHYDROGENASE; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG; VASCULOTROPIN; VINBLASTINE; VON HIPPEL LINDAU PROTEIN;

ALOPECIA; ANEMIA; ARTICLE; BLEEDING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CIGARETTE SMOKING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CRYOSURGERY; DESQUAMATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ERUPTION; DRUG FATALITY; DRUG WITHDRAWAL; ECHOGRAPHY; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HEMODIALYSIS; HEREDITY; HUMAN; HYPERAMYLASEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; LENGTH OF STAY; LYMPHOCYTOPENIA; MORBIDITY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHRECTOMY; NEUTROPENIA; OBESITY; OVERALL SURVIVAL; PARTIAL NEPHRECTOMY; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN INTERACTION; RADIOFREQUENCY ABLATION; RASH; SKIN MANIFESTATION; STOMATITIS; TACHYPHYLAXIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 33749598631     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl230     Document Type: Article

References (30)

1. Banks RE, Tirukonda P, Taylor C et al. Genetic and epigenelic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Research 2006; 66: 2000-2011.
2. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon-alpha-2b compared with interferon-alpha-2b alone for Metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-1659.
3. Mickisch GH, Garin A, van Poppel H et al. Radical nephrectomy plus interferon-alpha based immunotherapy compared with interferon alpha alone in Metastatic renal-cell carcinoma: A randomized trial. Lancet 2001; 358: 966-970.
4. Flanigan RC, Mickisch G, Sylvester R et al, Cytoreductive nephrectomy in patients with Metastatic renal cancer: A combined analysis. J Urol 2004; 171: 1071-1076.
5. Novick RC. Laparoscopic and Partial Nephrectomy. Clin Cancer Res 2004; 10: 6322s-6327s.
6. van der Werf-Messing B. Carcinoma of the kidney. Cancer 1973; 32: 1056-1061.
7. Juusela H, Malmio K, Alfthan O, Oravista KJ. Pre-operative irradiation in the treatment of renal adenocarcinoma. Scand J Urol 1977; 11: 277-281.
8. Finney R. The value of radiotherapy in the treatment of hypernephroma. A clinical trial. Brit J Urol 1973; 45: 258-269.
9. Kjaer M, Frederiksen PL, Engelholm AA. Post operative radiotherapy in stage II and III renal adenocarcinoma. A randomised trial by the Copenhagen renal cancer study group. Int J Rad Oncol Biol Phys 1987; 13: 665-672.
10. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993; 20(2): 303-321.
11. Small EJ, Motzer RJ. Interferon for renal cell carcinoma. In: Belldegrun A, Ritchie AWS, Figlin RA et al. (eds) Renal and adrenal tumors. New York: Oxford University Press, 2003: 381-387.
12. Cochrane Library.
13. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res 2004; 10: 6302s-6303s.
14. Bukowski RM, Negrier S, Elson P. Prognostic Factors in Patients with Advanced Renal Cell Carcinoma: Development of an International Kidney Cancer Working Group. Cancer 2004; 10: 6310s-6314s.
15. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6: 55s-57s.
16. Margolin KA, Rayner AA, Hawkins MJ et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 1989; 7(4): 486-98.
17. Baaten G, Voogd AC, Wagstaff J. A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer. Eur J Cancer 2004; 40: 1127-1144.
18. Yang JC et al.
19. Atkins M, Regan M, McDermott D et al. Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer. Clin Cancer Res 2005; 11: 3714-3721.
20. Upton MP, Parker R, Youmans AY et al. Histologic predictors of renal cell carcinoma response to interleukin-2 based therapy. J Immunother 2005; 28: 488-495.
21. Negrier S, Escudler B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338: 1272-1278.
22. van Herpen CM, Jansen RL, Krult WH et al, Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: A multicenter phase II study: Dutch Immunotherapy Working Party. Br J Cancer 2000; 82(4): 772-776.
23. Negrier S, Caty A, Lesimple T et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte contre le cancer. J Clin Oncol 2000; 18(24): 4009-4015.
24. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for Metastatic renal cell cancer. N Engl J Med 2003; 349: 427-434.
25. Hainsworth JD, Sosman JA, Spigel DR et al. Treatment of metastatc renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23: 7889-7896.
26. Escudier B, Szcylik C, Eisen T et al. Randomized phase III trial of the raff kinase and VEGFR inhibitor Sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2005; 23: 380s.
27. Retain MJ, Flaherty KT, Stadler WM et al. Preliminary anti-tumor activity of BAY 43-9006 in Metastatic renal cell carcinoma and other solid tumors in a phase II randomized discontinuation trial. Proc Am Soc Clin Oncol 2004; 23: 381s.
28. Ratain MJ, Eisen T, Stadler WM et al. Final findings from a phase II, placebo controlled, randomized discontinuation trial (RTD) of Sorafenib (BAY 43-9006) in patents with advanced renal cell carcinoma. Proc Am Soc Clin Oncoll 2005; 23: 388s.
29. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patents with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
30. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918.